• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Search on the site

  • About us
    • Governance
    • Team of Facilities
  • How to find us
  • Contact us
  • For you patient
  • EN
gemelli generator logo

GemelliGenerator

  • Facilities
    • Epidemiology & Biostatistics
    • Data Collection
    • Bioinformatics
    • Real World Data
  • Services
  • Research
    • Projects
    • Network Projects
    • Publications
  • Opportunity
    • Work with us
    • Courses
  • Network & Partners
  • News & Events
Home / Projects / MYC up-regulation confers vulnerability to dual inhibition of CDK12 and CDK13 in high-risk Group 3 medulloblastoma

MYC up-regulation confers vulnerability to dual inhibition of CDK12 and CDK13 in high-risk Group 3 medulloblastoma

Target:

Medulloblastoma (MB) is a prevalent childhood cerebellar malignancy, with MYC-amplified Group 3 tumors having the worst prognosis. MYC, an oncogenic transcription factor, is typically considered undruggable. However, targeting MYC-dependent processes, such as transcription and RNA processing regulation, offers promise.

In this study, MYC-driven Group 3 MB cells were tested for sensitivity to a range of transcription and splicing inhibitors, with a focus on THZ531, a CDK12/13 inhibitor. High-throughput RNA sequencing and bioinformatics analyses revealed that CDK12/13 inhibition selectively affects MYC-high Group 3 MB cells. Genes related to the DNA damage response (DDR) were up-regulated in Group 3 MB and repressed by CDK12/13 inhibition. CDK12/13 inhibition induced irreparable DNA damage in MYC-high Group 3 MB cells, particularly due to the higher RNA polymerase II elongation rate in DDR genes. Combining THZ531 with DNA damage-inducing agents effectively reduced the viability of MYC-high Group 3 MB cells.

This study identifies CDK12/13 as an exploitable vulnerability in MYC-high Group 3 MB, suggesting new therapeutic possibilities for this high-risk brain tumor.

 

DOI: https://doi.org/10.1186/s13046-023-02790-2

Primary Sidebar

Search

Our facilities

  • Epidemiology & Biostatistics
  • Data Collection
  • Bioinformatics
  • Real World Data

Latest from Gemelli Generator

  • 26/07/2022
    Azimuth, un percorso di digital health integrato per i pazienti con insufficienza cardiaca
  • 29/11/2021Events
    IL RUOLO DELLA BIOINFORMATICA NELLA RICERCA CLINICA: EVIDENZE E NUOVE PROSPETTIVE.
  • News
    25/10/2021Research
    L'intelligenza artificiale e la bellezza della guarigione
  • News
    09/09/2021Video
    Sanità. L'uso dell'Intelligenza artificiale nei servizi sanitari. Intervista al Prof. Vincenzo Valentini

Courses

Discover our courses

Need help?

Please use the form below based on your specific needs

Contact Us

Footer

  • Facilities
    • Epidemiology & Biostatistics
    • Data Collection
    • Bioinformatics
    • Real World Data
  • Services
  • Research
    • Projects
    • Network Projects
    • Publications
  • Opportunity
    • Work with us
    • Courses
  • Network & Partners
  • News & Events
  • About us
    • Governance
    • Team of Facilities
  • How to find us
  • Contact us
  • For you patient

Privacy information

Cookie Policy

Note

Usage conditions


Support us
gemelli generator footer
logo facebook
logo twitter
logo youtube
logo linkedin
logo policlinico gemelli
logo cattolica

© 2020 Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Codice Fiscale e P.IVA n. 13109681000

 

Sede Legale Largo Francesco Vito 1, 00168 Roma
Sede Operativa Largo Agostino Gemelli 8, 00168 Roma
Tutti i diritti riservati / All Rights Reserved – Credits